Developer docs
API playgroundTry for free, no card

Search company profiles

Dipharma S.A.

Full company profile

uuid000jtkc

Namestring
Dipharma S.A.
Legal namestring
DIPHARMA SA
Websiteurl
dipharma.ch
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Dipharma S.A. is a Swiss specialty pharmaceutical company, founded circa 2016 by Marc-Olivier Geinoz and headquartered in Chiasso, that develops and commercializes improved generic medicines for rare metabolic diseases. Its portfolio comprises four core products: Sapropterin Dipharma (for hyperphenylalaninemia/PKU and BH4 deficiency), Miglustat Dipharma (for Gaucher disease type 1 and Niemann-Pick type C), Nitisinone Dipharma (for hereditary tyrosinemia type 1), and Carglumsäure Waymade (carglumic acid, for hyperammonemia in Urea Cycle Disorders), supplemented by branded regional products such as Diterin® (South Korea) and Disanit® (EU). The core technical differentiator is formulation chemistry: Dipharma holds granted US patents on Miglustat (synthesis method US9079856B2 and crystalline form US8802155B1) and has filed international patents on a stable crystalline Nitisinone and stable capsule formulations, enabling room-temperature-stable presentations (up to 36 months for Miglustat and 2-3 years for Nitisinone) that eliminate the cold-chain requirements of originator products like Orfadin® and Zavesca®.

The company monetizes through a partner-based commercialization model: it supplies the active pharmaceutical ingredient and finished product to regional licensees/distributors (Amerigen for US Miglustat, Analog Pharma for US Nitisinone, Alvogen for South Korea, LogixX Pharma for UK Sapropterin, EffRx for Switzerland) and maintains direct field-sales presence only in Germany through its subsidiary Dipharma Arzneimittel GmbH. Pricing is quote-based, varies by market and payer, and is not publicly disclosed; in the US, patient assistance programs bring Nitisinone copays as low as $0. Approvals span FDA, EMA (centralized authorization in 31 EEA countries), MHRA, Swissmedic and Korean MFDS, with further registrations pending in Southeast Asia, the Middle East and Latin America.

The company operates with a small, capital-light footprint, leveraging the manufacturing and chemistry expertise of the founder's family CDMO group (Dipharma Francis Srl, Italy/USA) rather than owning large-scale production assets. It is privately held, has no disclosed external funding rounds, and is led by founder/CEO Marc-Olivier Geinoz, supported by an HR Director (Angela Tanieli). Customer segments are end-patient populations with rare inborn errors of metabolism, accessed indirectly through specialty pharmacies and national health systems, with payer cost pressure on orphan drugs providing the primary demand driver for affordable generic alternatives.

Short descriptiontext

Dipharma S.A. is a Swiss specialty pharmaceutical company that develops and commercializes improved generic drugs for rare metabolic diseases (PKU, Gaucher, Niemann-Pick, HT-1, Urea Cycle Disorders), distributing room-temperature stable formulations via regional partners and direct sales in Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChiasso, Switzerland
HQ citystring
Chiasso
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, orphan drugs, rare disease treatments, specialty pharma manufacturing, metabolic disorder therapies
Industry1 code
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product sales of generic orphan drugs
TypeOne Time License
Description

Dipharma SA generates revenue through the sale of improved generic pharmaceutical products for rare metabolic diseases, including Sapropterin Dipharma, Miglustat Dipharma, Nitisinone Dipharma, and Carglumsäure Waymade. Products are sold across multiple markets including EU, Switzerland, UK, USA, South Korea, and other regions through a network of commercial partners and direct sales in Germany.

dipharma.ch
2Licensing and co-development agreements
TypeLicensing Royalties
Description

Revenue is generated through licensing agreements with partners such as Amerigen, Analog Pharma, Alvogen, and LogixX Pharma. These partners commercialize Dipharma's products in specific territories (e.g., Amerigen for US Miglustat, Analog for US Nitisinone, Alvogen for South Korea) under exclusive collaboration agreements. Dipharma supplies the active pharmaceutical ingredient and receives licensing fees or revenue share.

dipharma.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Nitisinone Capsules (2mg, 5mg, 10mg, 20mg) - US market via Analog Pharma
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Available to eligible patients for as little as $0 per prescription through patient assistance programs. AB-rated generic equivalent of Swedish Orphan Biovitrum's Orfadin. The 20mg is the most commonly prescribed strength of Orfadin.

dipharma.ch
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Diterin
Description

Brand name for Sapropterin Dihydrochloride 100mg tablets, indicated for treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU).

dipharma.ch
+4 more records
Core offering1 text field

Dipharma SA develops, manufactures, and commercializes improved generic pharmaceutical products for rare metabolic diseases. Its portfolio includes Sapropterin Dipharma (for PKU/BH4 deficiency), Miglustat Dipharma (for Gaucher Disease Type 1 and Niemann-Pick Type C), Nitisinone Dipharma (for Hereditary Tyrosinemia Type 1), and Carglumsäure Waymade (for Urea Cycle Disorders). The company differentiates through proprietary room temperature stable formulations, superior purity, and bioequivalent delivery compared to originator orphan drugs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Miglustat Dipharma is the first generic version of Zavesca approved in the US and EU
+5 more records
Product overview1 text field

Dipharma S.A. is a Swiss specialty pharmaceutical company focused on developing and commercializing improved generic medicines for rare metabolic diseases. The company offers a portfolio of four core products: Sapropterin Dipharma (for Phenylketonuria and BH4 deficiency), Miglustat Dipharma (for Gaucher disease and Niemann-Pick Type C), Nitisinone Dipharma (for Hereditary Tyrosinemia Type 1), and Carglumsäure Waymade (for Urea Cycle Disorders). These are supported by branded regional products including Diterin® (South Korea) and Disanit® (EU). The company differentiates through improved formulations, particularly room temperature stability, and operates through a network of commercial partners globally.

Product and service4 records
1Sapropterin Dipharma (Diterin® in South Korea)
CategorySpecialty Pharmaceuticals - Orphan Drug
Description

Sapropterin Dihydrochloride 100mg soluble tablets and 100mg/500mg sachets for oral solution. A synthetic version of naturally occurring 6R-BH4 cofactor used to treat Hyperphenylalaninemia (HPA) in Phenylketonuria (PKU) patients and BH4 deficiency. Marketed as Diterin® in South Korea.

2Miglustat Dipharma
CategorySpecialty Pharmaceuticals - Orphan Drug
Description

Miglustat 100mg hard capsules. A glucosylceramide synthase inhibitor providing substrate reduction therapy for Gaucher Disease Type 1 and Niemann-Pick Disease Type C. Approved in EU, USA, and Switzerland. Can be stored at room temperature for 36 months.

3Nitisinone Dipharma (Disanit® in Europe)
CategorySpecialty Pharmaceuticals - Orphan Drug
Description

Nitisinone 2mg, 5mg, 10mg, and 20mg hard capsules. A competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase for treatment of Hereditary Tyrosinemia Type 1 (HT-1). Room temperature stable formulation with 2-year shelf life (extended to 3 years for 20mg capsules). Marketed as Disanit® in Europe.

4Carglumsäure Waymade
CategorySpecialty Pharmaceuticals - Orphan Drug
Description

Carglumsäure (Carglumic acid) 200mg tablets for oral suspension. A structural analog of N-acetylglutamate for treatment of hyperammonemia due to primary N-acetylglutamate synthase deficiency (Urea Cycle Disorders). Approved in selected EU countries.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-07
Description

Dipharma introduced an improved and protective packaging solution for its Sapropterin products, specifically designed for Far East countries. This aligns with high quality standards and improved solutions for patients.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-27
Description

Partnership with LogixX Pharma for the launch of Sapropterin Dihydrochloride in the United Kingdom. The MHRA granted Marketing Authorization for Sapropterin in June 2023, and the official UK launch was announced in October 2023. LogixX Pharma handles commercialization in the UK market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-31
Description

Additional FDA approval for 20 mg Nitisinone capsules (temperature stable). With the approval of the 20 mg capsule, Analog now has a full complement of room temperature stable strengths. The 20 mg is the most commonly prescribed strength of Orfadin®, bringing American HT-1 patients a room temperature stable treatment option. Available to eligible patients for as little as $0 per prescription. Stability at room temperature extended to 3 years for the 20 mg capsule.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-21
Description

Collaboration for FDA approval of Nitisinone ANDA (2, 5, 10 mg). Analog Pharma received final FDA approval for room temperature stable, AB-rated generic equivalent of Swedish Orphan Biovitrum's Orfadin® (Nitisinone capsules). Analog expects to distribute the product through specialty pharmacies beginning in Q3 2022. Dipharma's Nitisinone is bioequivalent to Orfadin® but can be stored at room temperature for 2 years.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-02-16
Description

Distribution agreement for Miglustat Dipharma in Switzerland. EffRx Pharmaceuticals SA is a company specialized in the commercialization of orphan drugs and distributes Miglustat Dipharma 100 mg capsules in Switzerland. The agreement marks another milestone in Dipharma's mission to offer improved solutions to patients suffering from inborn errors of metabolism.

6Amerigen Pharmaceuticals
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-04-18
Description

Exclusive collaboration between Amerigen and Dipharma in developing and commercializing Miglustat 100 mg capsules worldwide. Amerigen's ANDA for Miglustat 100 mg capsules received final FDA approval as the first generic equivalent to Actelion's Zavesca®. Amerigen's affiliates manufacture the finished product and commercialize it in the US, where it has already been launched. Dipharma supplies the miglustat active ingredient and holds two granted US patents (US9079856B2, US8802155B1). Amerigen has the right to enforce these patents in the US.

dipharma.ch
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-02-03
Description

Exclusive collaboration agreement between Dipharma S.A. and Alvogen for the commercialization of Diterin® (Sapropterin Dihydrochloride 100mg tablets) in the South Korean market. Alvogen holds exclusive rights to commercialize Diterin® 100mg tablets in Korea. Diterin® is the only drug approved in South Korea by the Korean Ministry of Food and Drug Safety for the treatment of HPA due to PKU. Dipharma is working to make Diterin® available in all countries worldwide.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

German subsidiary company (wholly owned or controlled) located in Limburg an der Lahn, Germany. Represents Dipharma's direct commercial presence in the German market. Phone: +49 (0)6431-284 3201.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty division of Recordati focused on rare and orphan diseases, with overlapping metabolic-disease portfolio and global distribution infrastructure. Comparable business model of addressing unmet needs in rare diseases through specialty pharmaceutical offerings.

TypeBroad incumbent
Description

US-based rare-disease biopharmaceutical company developing and commercializing therapies for metabolic and other rare genetic disorders. Comparable as a rare metabolic disease-focused commercial-stage company competing for the same specialist physician audience and payer budgets.

TypeBroad incumbent
Description

World's largest generic drug manufacturer with broad specialty and rare-disease exposure. Comparable as a potential competitor in generic orphan drugs and as a benchmark for global generic-pharma commercial scale that Dipharma accesses only through partners.

TypeOthers
Description

Related-family CDMO with four cGMP manufacturing sites in Italy and the USA, founded on the same Geinoz/Biazzi family heritage as Dipharma SA. Not a direct competitor but an ecosystem enabler that supplies manufacturing infrastructure and small-molecule API expertise underpinning Dipharma's product portfolio.

TypeDirect peer
Description

Polish-based developer and manufacturer of generic and biosimilar medicines with activity in specialty and rare-disease segments. Comparable as a European-headquartered specialty generics manufacturer pursuing complex small-molecule opportunities.

TypeBroad incumbent
Description

Originator of Kuvan (sapropterin) for PKU and broader rare-disease leader. Directly competes with Dipharma's Sapropterin Dipharma in PKU and represents the branded incumbent whose market share Dipharma is targeting with its generic alternative.

TypeDirect peer
Description

UK-based specialty pharma that develops improved formulations of existing drugs for rare diseases, with a focus on patient-friendly delivery and stability. Highly comparable to Dipharma in business model (improved generics for rare metabolic and orphan conditions) and target customer base (specialists and payers seeking better alternatives to originator orphan drugs).

TypeBroad incumbent
Description

Originator of Orfadin (Nitisinone) and broader rare-disease specialty pharma. Operates in the same therapeutic categories as Dipharma and competes directly through its branded Nitisinone franchise while also pursuing adjacent metabolic and hematology rare diseases.

TypeBroad incumbent
Description

Large Indian generic pharmaceutical manufacturer with extensive US and EU ANDA portfolios, including rare-disease products. Comparable as a competitor that could file ANDAs against Dipharma's molecules and as a benchmark for global generic-pharma scale and capital intensity.

10Actelion Pharmaceuticals (Janssen/J&J)
TypeBroad incumbent
Description

Originator of Zavesca (miglustat) for Gaucher disease and Niemann-Pick Type C. Now part of Janssen Pharmaceuticals. Competes with Dipharma's Miglustat Dipharma through the branded reference product that Dipharma's generic has been approved against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dipharma S.A.

Specialty Pharmaceuticalsdipharma.ch

Dipharma S.A. is a Swiss specialty pharmaceutical company that develops and commercializes improved generic drugs for rare metabolic diseases (PKU, Gaucher, Niemann-Pick, HT-1, Urea Cycle Disorders), distributing room-temperature stable formulations via regional partners and direct sales in Germany.

What Dipharma S.A. does

Dipharma S.A. is a Swiss specialty pharmaceutical company, founded circa 2016 by Marc-Olivier Geinoz and headquartered in Chiasso, that develops and commercializes improved generic medicines for rare metabolic diseases. Its portfolio comprises four core products: Sapropterin Dipharma (for hyperphenylalaninemia/PKU and BH4 deficiency), Miglustat Dipharma (for Gaucher disease type 1 and Niemann-Pick type C), Nitisinone Dipharma (for hereditary tyrosinemia type 1), and Carglumsäure Waymade (carglumic acid, for hyperammonemia in Urea Cycle Disorders), supplemented by branded regional products such as Diterin® (South Korea) and Disanit® (EU). The core technical differentiator is formulation chemistry: Dipharma holds granted US patents on Miglustat (synthesis method US9079856B2 and crystalline form US8802155B1) and has filed international patents on a stable crystalline Nitisinone and stable capsule formulations, enabling room-temperature-stable presentations (up to 36 months for Miglustat and 2-3 years for Nitisinone) that eliminate the cold-chain requirements of originator products like Orfadin® and Zavesca®.

The company monetizes through a partner-based commercialization model: it supplies the active pharmaceutical ingredient and finished product to regional licensees/distributors (Amerigen for US Miglustat, Analog Pharma for US Nitisinone, Alvogen for South Korea, LogixX Pharma for UK Sapropterin, EffRx for Switzerland) and maintains direct field-sales presence only in Germany through its subsidiary Dipharma Arzneimittel GmbH. Pricing is quote-based, varies by market and payer, and is not publicly disclosed; in the US, patient assistance programs bring Nitisinone copays as low as $0. Approvals span FDA, EMA (centralized authorization in 31 EEA countries), MHRA, Swissmedic and Korean MFDS, with further registrations pending in Southeast Asia, the Middle East and Latin America.

The company operates with a small, capital-light footprint, leveraging the manufacturing and chemistry expertise of the founder's family CDMO group (Dipharma Francis Srl, Italy/USA) rather than owning large-scale production assets. It is privately held, has no disclosed external funding rounds, and is led by founder/CEO Marc-Olivier Geinoz, supported by an HR Director (Angela Tanieli). Customer segments are end-patient populations with rare inborn errors of metabolism, accessed indirectly through specialty pharmacies and national health systems, with payer cost pressure on orphan drugs providing the primary demand driver for affordable generic alternatives.

Dipharma S.A. firmographics

Firmographics
Name
Dipharma S.A.
Legal name
DIPHARMA SA
Website
https://dipharma.ch
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Dipharma S.A. is a Swiss specialty pharmaceutical company that develops and commercializes improved generic drugs for rare metabolic diseases (PKU, Gaucher, Niemann-Pick, HT-1, Urea Cycle Disorders), distributing room-temperature stable formulations via regional partners and direct sales in Germany.
Ownership category
akta.pro rank

Dipharma S.A. industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Generic pharmaceuticals
  • Orphan drugs
  • Rare disease treatments
  • Specialty pharma manufacturing
  • Metabolic disorder therapies

Where Dipharma S.A. is headquartered

Location

Headquarters

HQ city
Chiasso
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Dipharma S.A. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product sales of generic orphan drugs: Dipharma SA generates revenue through the sale of improved generic pharmaceutical products for rare metabolic diseases, including Sapropterin Dipharma, Miglustat Dipharma, Nitisinone Dipharma, and Carglumsäure Waymade. Products are sold across multiple markets including EU, Switzerland, UK, USA, South Korea, and other regions through a network of commercial partners and direct sales in Germany.
  2. Licensing and co-development agreements: Revenue is generated through licensing agreements with partners such as Amerigen, Analog Pharma, Alvogen, and LogixX Pharma. These partners commercialize Dipharma's products in specific territories (e.g., Amerigen for US Miglustat, Analog for US Nitisinone, Alvogen for South Korea) under exclusive collaboration agreements. Dipharma supplies the active pharmaceutical ingredient and receives licensing fees or revenue share.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractNitisinone Capsules (2mg, 5mg, 10mg, 20mg) - US market via Analog Pharma

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Dipharma S.A. product offering

Product offering

Core offering

Dipharma SA develops, manufactures, and commercializes improved generic pharmaceutical products for rare metabolic diseases. Its portfolio includes Sapropterin Dipharma (for PKU/BH4 deficiency), Miglustat Dipharma (for Gaucher Disease Type 1 and Niemann-Pick Type C), Nitisinone Dipharma (for Hereditary Tyrosinemia Type 1), and Carglumsäure Waymade (for Urea Cycle Disorders). The company differentiates through proprietary room temperature stable formulations, superior purity, and bioequivalent delivery compared to originator orphan drugs.

Product overview

Dipharma S.A. is a Swiss specialty pharmaceutical company focused on developing and commercializing improved generic medicines for rare metabolic diseases. The company offers a portfolio of four core products: Sapropterin Dipharma (for Phenylketonuria and BH4 deficiency), Miglustat Dipharma (for Gaucher disease and Niemann-Pick Type C), Nitisinone Dipharma (for Hereditary Tyrosinemia Type 1), and Carglumsäure Waymade (for Urea Cycle Disorders). These are supported by branded regional products including Diterin® (South Korea) and Disanit® (EU). The company differentiates through improved formulations, particularly room temperature stability, and operates through a network of commercial partners globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Diterin: Brand name for Sapropterin Dihydrochloride 100mg tablets, indicated for treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU).
  • Disanit
  • Sapropterin Dipharma
  • Miglustat Dipharma
  • Nitisinone Dipharma

Products and services

  • Sapropterin Dipharma (Diterin® in South Korea) Sapropterin Dihydrochloride 100mg soluble tablets and 100mg/500mg sachets for oral solution. A synthetic version of naturally occurring 6R-BH4 cofactor used to treat Hyperphenylalaninemia (HPA) in Phenylketonuria (PKU) patients and BH4 deficiency. Marketed as Diterin® in South Korea.
  • Miglustat Dipharma Miglustat 100mg hard capsules. A glucosylceramide synthase inhibitor providing substrate reduction therapy for Gaucher Disease Type 1 and Niemann-Pick Disease Type C. Approved in EU, USA, and Switzerland. Can be stored at room temperature for 36 months.
  • Nitisinone Dipharma (Disanit® in Europe) Nitisinone 2mg, 5mg, 10mg, and 20mg hard capsules. A competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase for treatment of Hereditary Tyrosinemia Type 1 (HT-1). Room temperature stable formulation with 2-year shelf life (extended to 3 years for 20mg capsules). Marketed as Disanit® in Europe.
  • Carglumsäure Waymade Carglumsäure (Carglumic acid) 200mg tablets for oral suspension. A structural analog of N-acetylglutamate for treatment of hyperammonemia due to primary N-acetylglutamate synthase deficiency (Urea Cycle Disorders). Approved in selected EU countries.

Quantifiable outcome

  • Miglustat Dipharma is the first generic version of Zavesca approved in the US and EU
  • +5 more outcomes

Companies that use Dipharma S.A.

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Dipharma S.A. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Dipharma S.A. partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • LogixX PharmaminorChannel Partner/ Reseller/ Distributor · 7 May 2025Dipharma introduced an improved and protective packaging solution for its Sapropterin products, specifically designed for Far East countries. This aligns with high quality standards and improved solutions for patients.
  • LogixX PharmacoreChannel Partner/ Reseller/ Distributor · 27 June 2023Partnership with LogixX Pharma for the launch of Sapropterin Dihydrochloride in the United Kingdom. The MHRA granted Marketing Authorization for Sapropterin in June 2023, and the official UK launch was announced in October 2023. LogixX Pharma handles commercialization in the UK market.
  • Analog Pharma (member of Duchesnay Pharmaceutical Group)coreChannel Partner/ Reseller/ Distributor · 31 May 2023Additional FDA approval for 20 mg Nitisinone capsules (temperature stable). With the approval of the 20 mg capsule, Analog now has a full complement of room temperature stable strengths. The 20 mg is the most commonly prescribed strength of Orfadin®, bringing American HT-1 patients a room temperature stable treatment option. Available to eligible patients for as little as $0 per prescription. Stability at room temperature extended to 3 years for the 20 mg capsule.
  • Analog Pharma (member of Duchesnay Pharmaceutical Group)coreChannel Partner/ Reseller/ Distributor · 21 June 2022Collaboration for FDA approval of Nitisinone ANDA (2, 5, 10 mg). Analog Pharma received final FDA approval for room temperature stable, AB-rated generic equivalent of Swedish Orphan Biovitrum's Orfadin® (Nitisinone capsules). Analog expects to distribute the product through specialty pharmacies beginning in Q3 2022. Dipharma's Nitisinone is bioequivalent to Orfadin® but can be stored at room temperature for 2 years.
  • EffRx Pharmaceuticals SAcoreChannel Partner/ Reseller/ Distributor · 16 February 2021Distribution agreement for Miglustat Dipharma in Switzerland. EffRx Pharmaceuticals SA is a company specialized in the commercialization of orphan drugs and distributes Miglustat Dipharma 100 mg capsules in Switzerland. The agreement marks another milestone in Dipharma's mission to offer improved solutions to patients suffering from inborn errors of metabolism.
  • Amerigen PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 18 April 2018Exclusive collaboration between Amerigen and Dipharma in developing and commercializing Miglustat 100 mg capsules worldwide. Amerigen's ANDA for Miglustat 100 mg capsules received final FDA approval as the first generic equivalent to Actelion's Zavesca®. Amerigen's affiliates manufacture the finished product and commercialize it in the US, where it has already been launched. Dipharma supplies the miglustat active ingredient and holds two granted US patents (US9079856B2, US8802155B1). Amerigen has the right to enforce these patents in the US.
  • AlvogencoreChannel Partner/ Reseller/ Distributor · 3 February 2017Exclusive collaboration agreement between Dipharma S.A. and Alvogen for the commercialization of Diterin® (Sapropterin Dihydrochloride 100mg tablets) in the South Korean market. Alvogen holds exclusive rights to commercialize Diterin® 100mg tablets in Korea. Diterin® is the only drug approved in South Korea by the Korean Ministry of Food and Drug Safety for the treatment of HPA due to PKU. Dipharma is working to make Diterin® available in all countries worldwide.
  • Dipharma Arzneimittel GmbHcoreChannel Partner/ Reseller/ DistributorGerman subsidiary company (wholly owned or controlled) located in Limburg an der Lahn, Germany. Represents Dipharma's direct commercial presence in the German market. Phone: +49 (0)6431-284 3201.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Dipharma S.A. competitors and assessment

Company assessment

Broad incumbents

  • Recordati Rare Diseases: Specialty division of Recordati focused on rare and orphan diseases, with overlapping metabolic-disease portfolio and global distribution infrastructure. Comparable business model of addressing unmet needs in rare diseases through specialty pharmaceutical offerings.
  • Ultragenyx Pharmaceutical: US-based rare-disease biopharmaceutical company developing and commercializing therapies for metabolic and other rare genetic disorders. Comparable as a rare metabolic disease-focused commercial-stage company competing for the same specialist physician audience and payer budgets.
  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad specialty and rare-disease exposure. Comparable as a potential competitor in generic orphan drugs and as a benchmark for global generic-pharma commercial scale that Dipharma accesses only through partners.
  • BioMarin Pharmaceutical: Originator of Kuvan (sapropterin) for PKU and broader rare-disease leader. Directly competes with Dipharma's Sapropterin Dipharma in PKU and represents the branded incumbent whose market share Dipharma is targeting with its generic alternative.
  • Swedish Orphan Biovitrum (Sobi): Originator of Orfadin (Nitisinone) and broader rare-disease specialty pharma. Operates in the same therapeutic categories as Dipharma and competes directly through its branded Nitisinone franchise while also pursuing adjacent metabolic and hematology rare diseases.
  • Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with extensive US and EU ANDA portfolios, including rare-disease products. Comparable as a competitor that could file ANDAs against Dipharma's molecules and as a benchmark for global generic-pharma scale and capital intensity.
  • Actelion Pharmaceuticals (Janssen/J&J): Originator of Zavesca (miglustat) for Gaucher disease and Niemann-Pick Type C. Now part of Janssen Pharmaceuticals. Competes with Dipharma's Miglustat Dipharma through the branded reference product that Dipharma's generic has been approved against.

Others

  • Dipharma Francis Srl: Related-family CDMO with four cGMP manufacturing sites in Italy and the USA, founded on the same Geinoz/Biazzi family heritage as Dipharma SA. Not a direct competitor but an ecosystem enabler that supplies manufacturing infrastructure and small-molecule API expertise underpinning Dipharma's product portfolio.

Direct peers

  • Polpharma Biologics: Polish-based developer and manufacturer of generic and biosimilar medicines with activity in specialty and rare-disease segments. Comparable as a European-headquartered specialty generics manufacturer pursuing complex small-molecule opportunities.
  • Cycle Pharmaceuticals: UK-based specialty pharma that develops improved formulations of existing drugs for rare diseases, with a focus on patient-friendly delivery and stability. Highly comparable to Dipharma in business model (improved generics for rare metabolic and orphan conditions) and target customer base (specialists and payers seeking better alternatives to originator orphan drugs).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Dipharma S.A. social profiles

Digital presence

Dipharma S.A. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dipharma S.A. leadership team

Management profile

Number of profiles

Profiles4 records

Dipharma S.A. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dipharma S.A. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dipharma S.A.

What does Dipharma S.A. do?

Dipharma SA develops, manufactures, and commercializes improved generic pharmaceutical products for rare metabolic diseases. Its portfolio includes Sapropterin Dipharma (for PKU/BH4 deficiency), Miglustat Dipharma (for Gaucher Disease Type 1 and Niemann-Pick Type C), Nitisinone Dipharma (for Hereditary Tyrosinemia Type 1), and Carglumsäure Waymade (for Urea Cycle Disorders). The company differentiates through proprietary room temperature stable formulations, superior purity, and bioequivalent delivery compared to originator orphan drugs.

Is Dipharma S.A. a public or private company?

Dipharma S.A. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Dipharma S.A. founded?

Dipharma S.A. was founded in 2016. It employs 11 to 50 people.

Where is Dipharma S.A. based?

Dipharma S.A. is headquartered in Chiasso, Switzerland, in the Europe region.

How does Dipharma S.A. make money?

Two revenue lines are on record. Product sales of generic orphan drugs are the primary driver. The others are licensing and co-development agreements.

Who are Dipharma S.A.'s main competitors?

Broad incumbents on record are Recordati Rare Diseases, Ultragenyx Pharmaceutical, Teva Pharmaceutical Industries, BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Aurobindo Pharma and Actelion Pharmaceuticals (Janssen/J&J). Dipharma Francis Srl is listed as an others. Direct peers are Polpharma Biologics and Cycle Pharmaceuticals.

Does Dipharma S.A. have an API?

No public API is recorded for Dipharma S.A..

What industry is Dipharma S.A. in?

Dipharma S.A.'s product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterDipharma buys UK rare disease partner LogixX PharmaSwiss specialty pharmaceutical company Dipharma acquired UK partner LogixX Pharma, bringing its commercial operation for two rare metabolic disease medicines in the UK under direct ownership. Financial terms were not disclosed. The purchase gives privately held Dipharma its first direct commercial presence in the UK.PR NewswireAmerigen and Dipharma Announce U.S. FDA Approval for Generic Miglustat 100 mg CapsulesAmerigen Pharmaceuticals and Dipharma S.A. announced that their Abbreviated New Drug Application for Miglustat 100 mg capsules received final FDA approval, making it the first generic equivalent to Actelion Pharmaceuticals' Zavesca® approved in the U.S. The collaboration involved Dipharma supplying the active ingredient and holding the relevant patents, while Amerigen's affiliates will manufacture the finished product and commercialize it in the U.S. market. This marks Amerigen's fifth U.S. product launch and third first-to-market generic, with both companies highlighting the cost savings this approval will bring to the American healthcare system.PR NewswireAMERIGEN and DIPHARMA announce first regulatory submission for Miglustat 100mg CapsulesAmerigen Pharmaceuticals Limited and Dipharma S.A. announced the submission of an Abbreviated New Drug Application for Miglustat 100mg Capsules to the US FDA. The filing is the first regulatory outcome of an exclusive collaboration between the two companies to develop and commercialize a generic equivalent of Zavesca® for markets worldwide. Miglustat is used to treat rare diseases, and the submission marks a strategic milestone advancing the drug toward market entry.